Written by Merkel cell carcinoma is a rare but highly aggressive form of skin cancer known for its rapid growth and tendency to metastasize. Despite the promise of immune checkpoint blockade therapy, which can boost the body’s immune response against cancer cells, nearly half of patients do not respond to this treatment. A new study published today in Cancer Discovery is providing insights into why some Merkel cell carcinoma patients respond to this type of immunotherapy while others do not.
Medical Xpress – latest medical and health news stories